ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 32 for:    Recruiting, Not yet recruiting, Available Studies | "Vision, Low"

Measuring of Neuro-visual Functionality With Ocusweep

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02258113
Recruitment Status : Recruiting
First Posted : October 7, 2014
Last Update Posted : October 17, 2017
Sponsor:
Information provided by (Responsible Party):
Ocuspecto Oy

Brief Summary:
The aim of this study is to measure visual acuity and contrast sensitivity using a novel reaction-time based visual field device Ocusweep compared to widely used methods. Addition to that. the aim is to validate a novel perimetry method (Visual Search Test, VST) which is based on reaction times in visual decision-making task, where the subject is allowed to move eyes and where the fixation is verified by the subject himself in contrast to standard automatic perimetry (SAP) where prolonged stationary fixation and external fixation monitoring apparatus is required. using a novel reaction-time based visual field device Ocusweep compared to generally used SAP methods. Those tests will be done for healthy volunteers and for persons with diagnosed eye or brain disease.

Condition or disease Intervention/treatment Phase
Visual Impairment Device: Ocusweep Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Measuring of Neuro-visual Functionality With New Human Visual System Device Ocusweep
Study Start Date : November 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 31, 2017

Arm Intervention/treatment
LEA numbers, Pelli-Robson, Octopus
Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
Device: Ocusweep
A novel reaction-time based visual field device.




Primary Outcome Measures :
  1. Visual acuity [ Time Frame: One visit per one patient (1h/visit) ]
    Visual acuity is measured as logMAR unit at the one visit for each patient using a novel reaction-time based visual field device and comparable method.


Secondary Outcome Measures :
  1. Contrast sensitivity [ Time Frame: One visit per one patient (1h/visit) ]
    Contrast sensitivity is measured as logCS unit at the one visit for each patient using a novel reaction-time based visual field device and comparable method.

  2. Reaction time [ Time Frame: One visit per one patient (1h/visit) ]
    Reaction time is measured using a novel reaction-time based visual field device and compared with generally used visual field program.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers
  • Persons suffering diagnosed eye disease
  • Persons suffering diagnosed brain disease

Exclusion Criteria:

  • No diabetes
  • Only one diagnosed disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02258113


Contacts
Contact: Marika Ojala, Mrs marika.ojala@ocuspecto.com
Contact: Markku Leinonen, Dr markku.leinonen@ocuspecto.com

Locations
Finland
Ocuspecto Oy Recruiting
Turku, Finland, 20100
Contact: Marika Ojala, MSc       marika.ojala@ocuspecto.com   
Contact: Markku Leinonen, Dr       markku.leinonen@ocuspecto.com   
Sponsors and Collaborators
Ocuspecto Oy

Responsible Party: Ocuspecto Oy
ClinicalTrials.gov Identifier: NCT02258113     History of Changes
Other Study ID Numbers: T109/2014
First Posted: October 7, 2014    Key Record Dates
Last Update Posted: October 17, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Vision Disorders
Vision, Low
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms